CIK 0001425205 · Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753254381
- Phone
- 6502607120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-02 | BILINSKY IGOR Chief Operating Officer | Shares withheld for taxes | −6,250 | $2.19 | $14K | 99,689 |
| 2025-09-02 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −3,516 | 7,033 | ||
| 2025-09-02 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −8,790 | 52,738 | ||
| 2025-08-06 | Roche Corleen M. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2025-08-06 | Roche Corleen M. Chief Financial Officer | Grant or award · Restricted Stock Units | +150,000 | 150,000 | ||
| 2025-06-13 | Countouriotis Athena Director | Grant or award · Deferred Restricted Stock Unit | +67,546 | 67,546 | ||
| 2025-06-13 | Maynard Ryan D Director | Grant or award · Deferred Restricted Stock Unit | +67,546 | 67,546 | ||
| 2025-06-13 | WEISER MICHAEL Director | Grant or award · Deferred Restricted Stock Unit | +67,546 | 67,546 | ||
| 2025-06-13 | Dukes Iain D. Director | Grant or award · Deferred Restricted Stock Unit | +135,092 | 135,092 | ||
| 2025-06-13 | YARNO WENDY L Director | Grant or award · Deferred Restricted Stock Unit | +67,546 | 67,546 | ||
| 2025-06-05 | Kirby Daniel Gordon Chief Commercial Officer | Purchase | +30,000 | $1.84 | $55K | 30,000 |
| 2025-06-02 | Puri Raj K. Chief Regulatory Officer | Option exercise | +5,469 | 212,321 | ||
| 2025-06-02 | Puri Raj K. Chief Regulatory Officer | Shares withheld for taxes | −2,467 | $1.76 | $4K | 209,854 |
| 2025-06-02 | Puri Raj K. Chief Regulatory Officer | Option exercise · Restricted Stock Units | −5,469 | 38,287 | ||
| 2025-06-02 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +52,085 | 426,731 | ||
| 2025-06-02 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −22,127 | $1.76 | $39K | 404,604 |
| 2025-06-02 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −10,417 | 31,252 | ||
| 2025-06-02 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −41,668 | 291,682 | ||
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise | +12,695 | 105,608 | ||
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Shares withheld for taxes | −6,448 | $1.76 | $11K | 99,160 |
Page 8 of 14 · 280 trades